Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
Abstract
In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492 ), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free survival (PFS) benefit versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated intermediate- or high-risk diffuse large B-cell lymphoma (DLBCL; median follow-up: 28 months). In this 5-year update, sustained PFS benefits favoring Pola-R-CHP were observed. In the global intention-to-treat population (N = 879; median follow-up: 64.1 months), Pola-R-CHP demonstrated a significant PFS benefit over R-CHOP (hazard ratio [HR], 0.77 [95% CI, 0.62 to 0.97]), with 5-year PFS rates of 64.9% (95% CI, 59.8 to 70.0) and 59.1% (95% CI, 53.9 to 64.3), respectively. Although not statistically significant, overall survival analysis showed a HR of 0.85 (95% CI, 0.63 to 1.15) at the 5-year data cut compared with 0.94 (95% CI, 0.67 to 1.33) at the 2-year data cut. In the expanded population, 46 and 62 patients had lymphoma-related deaths in the Pola-R-CHP and R-CHOP arms, respectively. Exploratory analyses showed favorable 5-year survival rates with Pola-R-CHP in high-risk subgroups, including activated B-cell DLBCL and International Prognostic Index score 3-5. Long-term tolerability was similar between treatment arms. Findings confirm Pola-R-CHP represents a standard of care for frontline treatment of DLBCL.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (37)
Franck Morschhauser
Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France
Gilles Salles
41Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
Laurie H. Sehn
8Division of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, Canada
Alex F. Herrera
10Duarte Cancer Center, City of Hope Medical Center, Duarte, CA
Jonathan W. Friedberg
18Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
Marek Trneny
Georg Lenz
Jeff P. Sharman
1Willamette Valley Cancer Institute, Sarah Cannon Research, Eugene, OR
Charles Herbaux
John M. Burke
4Rocky Mountain Cancer Centers, US Oncology Research, Aurora, CO
Matthew Matasar
6Rutgers Cancer Institute, New Brunswick, United States
Graham P. Collins
32Department of Clinical Haematology, Oxford University Hospital, Oxford, United Kingdom
Neha Mehta-Shah
3Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
Lucie Oberic
7Oncopole, Hematology, Toulouse, France
Adrien Chauchet
20CHU de Besançon – Hôpital Jean Minjoz, Besancon, France
Wojciech Jurczak
Yuqin Song
Antonio Pinto
15Department of Hematology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico “Fondazione G Pascale”, Naples, Italy
Shinya Rai
2British Columbia Cancer, Centre for Lymphoid Cancer, Vancouver, Canada
Koji Izutsu
National Cancer Center Hospital, Tokyo, Japan
Richard Greil
Larysa Mykhalska
Juan M. Bergua-Burgués
Matthew C. Cheung
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Ho-jin Shin
Pusan National University Hospital, Busan, Korea, Republic of
Greg Hapgood
10Princess Alexandra Hospital, Department of Haematology, Brisbane, Australia
Eduardo Munhoz
1Hospital Erasto Gaertner / Instituto de Oncologia do Paraná, Hematoncology / BMT, Curitiba, Brazil
Pau Abrisqueta
Jyh-Pyng Gau
Yanwen Jiang
12Genentech, Inc, South San Francisco, CA
Bruce McCall
Genentech, Inc, South San Francisco, CA
Saibah Chohan
Matthew Sugidono
14Genentech, Inc., South San Francisco, CA
Mark Yan
15Hoffmann-La Roche Ltd, Mississauga, ON, Canada
Connie Lee Batlevi
12Genentech, Inc, South San Francisco, CA
Hervé Tilly
5Service Hématologie, Centre Henri Becquerel, Rouen, France
Christopher R. Flowers
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine